Press release
Leptomeningeal Metastases Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer
"Leptomeningeal Metastases Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Leptomeningeal Metastases Market.
The Leptomeningeal Metastases Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Leptomeningeal Metastases Pipeline Report: https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Leptomeningeal Metastases treatment therapies with a considerable amount of success over the years.
• Leptomeningeal Metastases companies working in the treatment market are NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, Plus Therapeutics, Angiochem, Y-mAbs Therapeutics, and others, are developing therapies for the Leptomeningeal Metastases treatment
• Emerging Leptomeningeal Metastases therapies in the different phases of clinical trials are- Rhenium-186, AZD1390, TY-9591, ANG1005, Rhenium-186 NanoLiposome (186RNL), Paclitaxel trevatide (ANG1005), Omburtamab, and others are expected to have a significant impact on the Leptomeningeal Metastases market in the coming years.
• In December 2023, Angiochem will initiate a Randomized Open-Label, Multi-Center PivotalStudy of ANG1005 Compared With Physician's Best Choice in HER2-Negative Breast Cancer Patients WithNewly Diagnosed Leptomeningeal Carcinomatosis and Previously Treated Brain Metastases (ANGLeD). This is an open-label Phase 3 study to see if ANG1005 can prolong survival compared to a Physician Best Choice Control in HER2-negative breast cancer patients with newly diagnosed leptomeningeal disease and previously treated brain metastases.
Leptomeningeal Metastases Overview
Leptomeningeal metastases, also known as leptomeningeal carcinomatosis or leptomeningeal disease, occur when cancer cells spread from their original site (primary tumor) to the membranes surrounding the brain and spinal cord, known as the meninges.
Get a Free Sample PDF Report to know more about Leptomeningeal Metastases Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Emerging Leptomeningeal Metastases Drugs Under Different Phases of Clinical Development Include:
• Rhenium-186: NanoLiposome Plus Therapeutics
• AZD1390: AstraZeneca
• TY-9591: TYK Medicine
• ANG1005: Angiochem
• Rhenium-186 NanoLiposome (186RNL): Plus Therapeutics
• Paclitaxel trevatide (ANG1005): Angiochem
• Omburtamab: Y-mAbs Therapeutics
Leptomeningeal Metastases Pipeline Therapeutics Assessment
• Leptomeningeal Metastases Assessment by Product Type
• Leptomeningeal Metastases By Stage and Product Type
• Leptomeningeal Metastases Assessment by Route of Administration
• Leptomeningeal Metastases By Stage and Route of Administration
• Leptomeningeal Metastases Assessment by Molecule Type
• Leptomeningeal Metastases by Stage and Molecule Type
DelveInsight's Leptomeningeal Metastases Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Further Leptomeningeal Metastases product details are provided in the report. Download the Leptomeningeal Metastases pipeline report to learn more about the emerging Leptomeningeal Metastases therapies at:
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the key companies in the Leptomeningeal Metastases Therapeutics Market include:
Key companies developing therapies for Leptomeningeal Metastases are - Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
Leptomeningeal Metastases Pipeline Analysis:
The Leptomeningeal Metastases pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Leptomeningeal Metastases with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Leptomeningeal Metastases Treatment.
• Leptomeningeal Metastases key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Leptomeningeal Metastases Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Leptomeningeal Metastases market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Leptomeningeal Metastases drugs and therapies-
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Leptomeningeal Metastases Pipeline Market Drivers
• Increasing Prevalence of Leptomeningeal Metastases, increase in research and developmental activities are some of the important factors that are fueling the Leptomeningeal Metastases Market.
Leptomeningeal Metastases Pipeline Market Barriers
• However, high-cost associated with the disease, side-effects associated with the treatment and other factors are creating obstacles in the Leptomeningeal Metastases Market growth.
Scope of Leptomeningeal Metastases Pipeline Drug Insight
• Coverage: Global
• Key Leptomeningeal Metastases Companies: NanoLiposome Plus Therapeutics, AstraZeneca, TYK Medicine, Angiochem, Plus Therapeutics, Angiochem, Y-mAbs Therapeutics, and others
• Key Leptomeningeal Metastases Therapies: Rhenium-186, AZD1390, TY-9591, ANG1005, Rhenium-186 NanoLiposome (186RNL), Paclitaxel trevatide (ANG1005), Omburtamab, and others
• Leptomeningeal Metastases Therapeutic Assessment: Leptomeningeal Metastases current marketed and Leptomeningeal Metastases emerging therapies
• Leptomeningeal Metastases Market Dynamics: Leptomeningeal Metastases market drivers and Leptomeningeal Metastases market barriers
Request for Sample PDF Report for Leptomeningeal Metastases Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/leptomeningeal-metastases-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1. Leptomeningeal Metastases Report Introduction
2. Leptomeningeal Metastases Executive Summary
3. Leptomeningeal Metastases Overview
4. Leptomeningeal Metastases- Analytical Perspective In-depth Commercial Assessment
5. Leptomeningeal Metastases Pipeline Therapeutics
6. Leptomeningeal Metastases Late Stage Products (Phase II/III)
7. Leptomeningeal Metastases Mid Stage Products (Phase II)
8. Leptomeningeal Metastases Early Stage Products (Phase I)
9. Leptomeningeal Metastases Preclinical Stage Products
10. Leptomeningeal Metastases Therapeutics Assessment
11. Leptomeningeal Metastases Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Leptomeningeal Metastases Key Companies
14. Leptomeningeal Metastases Key Products
15. Leptomeningeal Metastases Unmet Needs
16 . Leptomeningeal Metastases Market Drivers and Barriers
17. Leptomeningeal Metastases Future Perspectives and Conclusion
18. Leptomeningeal Metastases Analyst Views
19. Appendix
20. About DelveInsight
Related Reports:
Leptomeningeal Metastases Market https://www.delveinsight.com/report-store/leptomeningeal-metastases-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Leptomeningeal Metastases Epidemiology https://www.delveinsight.com/report-store/leptomeningeal-metastases-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Leptomeningeal Metastases Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Latest Reports:
Ischemia-reperfusion Injury Market https://www.delveinsight.com/report-store/ischemia-reperfusion-injury-market
DelveInsight's report titled "Ischemia-reperfusion injury Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes historical and projected epidemiological data concerning Ischemia-reperfusion injury. This analysis includes a breakdown of the Incident Cases of Ischemia-reperfusion injury, Organ-specific Incident Cases of Ischemia-reperfusion injury, Gender-specific Incident Cases of Ischemia-reperfusion Injury, and Age-specific Incident Cases of Ischemia-reperfusion Injury.
Meniscus Tear Market
https://www.delveinsight.com/report-store/meniscus-tear-market
DelveInsight's report titled "Meniscus Tear Market Insights, Epidemiology, and Market Forecast -2032" provides a comprehensive analysis of Meniscus Tear. The report includes a detailed examination of the historical and projected epidemiology data that includes Total Incident Cases of Meniscus Tear, Gender-specific Incident Cases of Meniscus Tear, Age-specific Incident Cases of Meniscus Tear, Treatable Cases of Meniscus Tear.
Functional Dyspepsia Market https://www.delveinsight.com/report-store/functional-dyspepsia-market-insights
DelveInsight's "Functional Dyspepsia Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Functional Dyspepsia, historical and forecasted epidemiology as well as the Functional Dyspepsia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Diphtheria Market
https://www.delveinsight.com/report-store/diphtheria-market
DelveInsight's report titled "Diphtheria Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes diphtheria. The report includes a detailed examination of the historical and projected epidemiology data that includes incident cases of diphtheria segmented by age and type.
Chronic Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
DelveInsight's report titled "Chronic Constipation Market Insights, Epidemiology, and Market Forecast - 2032" comprehensively analyzes Chronic constipation. The report includes a detailed examination of the historical and projected epidemiology data, including Total Prevalent Cases, Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, and Age-specific Diagnosed Prevalent cases of Chronic Constipation.
Pulmonary Fibrosis Market
https://www.delveinsight.com/report-store/pulmonary-fibrosis-market
DelveInsight's "Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Pulmonary Fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+91-9650213330
Healthcare Consulting
https://www.delveinsight.com/consulting-services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Leptomeningeal Metastases Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer here
News-ID: 3343788 • Views: …
More Releases from DelveInsight Business Research
Global Tumor Ablation Market to reach USD 4,595.68 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The global Tumor Ablations (EHR) market is experiencing significant growth, driven by the increasing prevalence of chronic diseases that require continuous monitoring, data management, and coordinated long-term care. This demand has fueled the need for integrated healthcare systems capable of connecting patient information across multiple departments and care settings. To support this trend, governments worldwide are introducing initiatives, funding, mandates, and regulatory frameworks to promote EHR…
Global Spinal Implants Market to reach USD 21,899.24 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing prevalence of spinal disorders, especially among the aging population, has substantially driven the demand for corrective surgical procedures. At the same time, the rise in sports-related and trauma-induced spinal injuries is boosting the need for advanced implantable solutions. Additionally, there is a growing preference for non-fusion and motion-preserving devices that maintain spinal mobility and improve patient outcomes, particularly among younger and more active individuals.…
Global Vascular Stents Market to reach USD 18,277.68 million by 2032 at a CAGR o …
According to DelveInsight's analysis, The increasing global incidence of cancer is boosting the demand for effective treatment options such as tumor ablation. Minimally invasive procedures are becoming more popular due to their shorter recovery periods, reduced risks, and cost-effectiveness compared to conventional surgery. At the same time, technological advancements in tumor ablation devices-such as improvements in radiofrequency, microwave, and cryoablation technologies-have enhanced precision, safety, and effectiveness, making these procedures increasingly…
Global Vascular Grafts Market to reach USD 3,153.39 million by 2032 at a CAGR of …
According to DelveInsight's analysis, The increasing prevalence of cardiovascular disorders, along with risk factors like hypertension, diabetes, and obesity, is fueling the demand for surgical interventions, thereby supporting the growth of the vascular graft market. Moreover, greater awareness and the expansion of cardiovascular screening programs are enabling earlier diagnosis and timely treatment, further driving the need for vascular grafts.
DelveInsight's "Vascular Grafts Market Insights, Competitive Landscape and Market Forecast-2032" report provides…
More Releases for Leptomeningeal
Leptomeningeal Metastases Market Size, Share and Growth Report, 2034
Introduction
The Leptomeningeal Metastases (LM) market is gaining increased attention as survival rates for primary cancers improve, leading to higher detection of late-stage complications like LM. This rare but severe condition occurs when cancer cells spread to the leptomeninges and cerebrospinal fluid (CSF), most often from breast cancer, lung cancer, or melanoma. Historically associated with poor prognosis, LM treatment is evolving with advancements in molecular diagnostics, targeted therapies, intrathecal drug delivery…
Trailhead Biosystems® Develops iPSC-Derived Vascular Leptomeningeal Cells
Beachwood, Ohio, March 5, 2025 - Trailhead Biosystems, Inc. (trailbio.com), a biotechnology company pioneering the creation of iPSC-derived human cells at scale for drug discovery and cell therapy, proudly announces the launch of TrailBio® Vascular Leptomeningeal Cells. As the first of their kind on the market, these unique cells provide researchers with a new tool to directly study the blood-brain barrier's permeability and regulatory mechanisms. This advancement represents a significant…
Leptomeningeal Metastases Market Anticipated to Expand Rapidly During 2024-2034, …
The Leptomeningeal Metastases market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Leptomeningeal Metastases pipeline products will significantly revolutionize the Leptomeningeal Metastases market dynamics.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United…
Leptomeningeal Metastases Drugs Market 2034: EMA, PDMA, FDA Approvals, Clinical …
Leptomeningeal Metastases companies are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Leptomeningeal Metastases…
Leptomeningeal Metastases Treatment Market 2034: EMA, PDMA, FDA Approvals, Clini …
Leptomeningeal Metastases companies working in the market are Plus Therapeutics, AstraZeneca, Angiochem, Y-mAbs Therapeutics, TYK Medicines, Inc, Seagen Inc., Pfizer, Genentech, Inc., Angiochem Inc, Daiichi Sankyo, Inc., and others.
(Albany, USA) DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Leptomeningeal Metastases, historical and forecasted epidemiology as well as the Leptomeningeal Metastases market trends in the United States, EU5 (Germany, Spain, Italy, France, and United…
Leptomeningeal Metastases Treatment Market Size, Forecast, Drugs, and Companies …
Leptomeningeal Metastases Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Leptomeningeal Metastases Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.
DelveInsight's "Leptomeningeal Metastases Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of the Leptomeningeal Metastases, historical and…
